Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitreosolve in diabetic retinopathy
NCT00664183Phase 3Terminated
- Sponsor
- VitreoRetinal Technologies, Inc.
- Start
- Mar 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Vitreosolve in diabetic retinopathy (DR) (2 arms), sponsored by VitreoRetinal Technologies, Inc. Primary endpoint: Ultrasound Assessment of Posterior Vitreous Detachment at 7 months. Started Mar 2008; status: terminated.
02
Drugs
Vitreosolve
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT00664183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00664183.